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Provenance: Written by editorial staff; not externally peer reviewed decisions and options. The editorial team is actively engaging with the cancer genomics community, both through our academic editors, such as Andrew Beck (Dana-Farber/ Harvard Cancer Center) who discussed the importance of open access to cancer genomics data in a recent editorial [18] , and also via our attendance at key conferences in 2015. Two consortia that provide broad public access to cancer sequence data are The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov/) and International Cancer Genome Consortium (ICGC, https://icgc.org/). We are very pleased to feature an accompanying interview blog [19] with Francis Ouellette, Associate Director of Informatics and Biocomputing at the Ontario Institute for Cancer Research, who discusses the remit of the ICGC and TCGA projects, how these projects have generated a tidal wave of data that has reshaped how people consider analyzing such datasets, and his hopes for how these findings will translate into clinical applications.
To coincide with the meeting of the American Association for Cancer Research (AACR), to be held in Philadelphia from April 18 to 22, 2015, PLOS Medicine is launching a Cancer Research Collection [20] , an open-access collection of recently published articles representing the full spectrum of clinically relevant cancer research and commentary, from translational to clinical to epidemiological. To expand the collection, and to support the mission we share with the AACR to conquer cancer through research and education, we are issuing a call to the clinical genomics and cancer research community for papers that provide novel insights into cancer heterogeneity, progression, and translational and clinical medicine, with strong potential to advance patient care, public policy, or clinical research agendas. Papers submitted in response to the call for papers will be included in the collection if accepted for publication. Please submit a presubmission inquiry to the editorial team at http://www.editorialmanager.com/pmedicine/ default.aspx.
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